Clinical Study
Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases
Table 1
Patient characteristics.
| | Case | Age (y)/sex | Histology | PS | Smoking status | EGFR mutation | Viral hepatitis B/C | Alcoholic liver injury | Liver metastasis | Pretreatment before gefitinib |
| | 1 | 50/F | Ad | 2 | smoker | positive | −/− | − | − | − | | 2 | 51/F | Ad | 1 | smoker | positive | −/− | − | − | + | | 3 | 61/M | Ad | 2 | non | positive | −/− | − | − | + | | 4 | 64/F | Ad | 3 | smoker | positive | −/− | − | − | − | | 5 | 64/F | Ad | 1 | smoker | unknown | −/− | − | − | + | | 6 | 66/F | Ad | 2 | non | positive | −/− | − | − | + | | 7 | 72/M | Ad | 3 | smoker | unknown | −/− | − | − | − | | 8 | 76/F | Ad | 0 | non | positive | −/− | − | − | + |
|
|
Abbreviations: Ad: adenocarcinoma; EGFR: epidermal growth factor receptor; PS: performance status.
|
